\
&
Contact us
\
&
Contact us
Published on | 1 year ago
ProgrammesThe European Commission invites stakeholders to provide feedback on the Chips Act to evaluate its effectiveness and identify potential adaptations. The consultation period runs from September 5, 2025, for twelve weeks.
The European Commission has launched a public consultation and a call for evidence concerning the evaluation and review of the Chips Act. This is part of an effort to ensure that the legislation remains relevant and effective amid changing market, technological, and geopolitical conditions. Stakeholders are encouraged to contribute their views on the current operation of the Chips Act and propose ways to adapt it to better support Europe's semiconductor ecosystem, including simplifications where necessary.
Participation is welcomed from a diverse range of stakeholders, including:
The feedback collected will inform the evaluation report and help identify necessary adjustments to ensure the framework supports Europe's semiconductor ambitions effectively. The public consultation details can be found on the Commission's Have Your Say portal.
The consultation period runs for twelve weeks, starting from 5 September 2025.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Research Infrastructures Health Horizontal Activities
The Bridging actions call in the updated Horizon Europe work programme 2026-2027 Horizontal Activities includes three grants to identified beneficiaries, i.e. not open calls for proposals, with a total earmarked budget of 65 million euro. The explanation provided by the European Commission for the earmarked budget for three life sciences databases... read more
Digital, Industry & Space AI Continent
The Digital Europe-funded project LLM-Bridge has issued a cascade funding call to fund a high-quality, EU-based incubator capable of supporting startups in the transforming of early-stage GenAI ideas into viable, scalable, and ethically compliant ventures. read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
